참고문헌
- Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002;38(Suppl 5):S39-S51.
- Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-1269.
- Miettinen M, Lasota J. Gastrointestinal stromal tumors-- definition, clinical, histological, immunohistochemical, and molecular genetic features and diff erential diagnosis. Virchows Arch 2001;438:1-12. https://doi.org/10.1007/s004280000338
- Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-1095. https://doi.org/10.1016/S0016-5085(98)70079-4
- Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, et al. Eff ect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-4300.
- Franquemont DW. Diff erentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-47.
- Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999;34:416-424. https://doi.org/10.1046/j.1365-2559.1999.00643.x
- Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-676. https://doi.org/10.1053/hupa.2002.124116
- Amin MB, Ma CK, Linden MD, Kubus JJ, Zarbo RJ. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Correlation with mitotic count and clinical outcome. Am J Clin Pathol 1993;100:428-432.
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465. https://doi.org/10.1053/hupa.2002.123545
- Saleem A, Charnley N, Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 2006;42:1720-1727. https://doi.org/10.1016/j.ejca.2006.02.021
- Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18F-fl uorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005;29:1429-1435. https://doi.org/10.1007/s00268-005-0045-6
- Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-483. https://doi.org/10.1053/hupa.2002.124123
- Appelman HD. Mesenchymal tumors of the gut: historical perspectives, new approaches, new results, and does it make any diff erence? Monogr Pathol 1990;(31):220-246.
- Somerhausen Nde S, Fletcher CD. Gastrointestinal stromal tumours: an update. Sarcoma 1998;2:133-141. https://doi.org/10.1080/13577149877885
- Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer 1977;39:255-262. https://doi.org/10.1002/1097-0142(197701)39:1<255::AID-CNCR2820390139>3.0.CO;2-H
- Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985;56:2242-2250. https://doi.org/10.1002/1097-0142(19851101)56:9<2242::AID-CNCR2820560918>3.0.CO;2-5
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58. https://doi.org/10.1097/00000658-200001000-00008
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Effi cacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480. https://doi.org/10.1056/NEJMoa020461
- Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60-S65.
- Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990;96(Pt 1):121-129.
- Scholzen T, Gerdes J. Th e Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
- Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2-11. https://doi.org/10.1046/j.1365-2559.2002.01343.x
- Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol 2000;99:563-570. https://doi.org/10.1007/s004010051161
- Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000;27:179-189. https://doi.org/10.1016/S0094-0143(05)70246-9
- Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000;19:471-475.
- Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007;42:633-641. https://doi.org/10.1080/00365520601040450
- Franquemont DW. Diff erentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-47.
- Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667. https://doi.org/10.1016/S0016-5085(03)01046-1
- Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005;11(2 Pt 1):638-645.
피인용 문헌
- A Case of Duodenal Leiomyoma Showing False Positive Fluorine-18-fluorodeoxyglucose Positron-Emission Tomography vol.12, pp.3, 2012, https://doi.org/10.7704/kjhugr.2012.12.3.198
- The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors vol.43, pp.10, 2011, https://doi.org/10.1007/s00595-012-0411-6
- The Usefulness of Preoperative 18FDG Positron-Emission Tomography and Computed Tomography for Predicting the Malignant Potential of Gastrointestinal Stromal Tumors vol.31, pp.2, 2011, https://doi.org/10.1159/000357149
- Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18F-FDG PET: Feasibility of a Metabolic Grading System vol.55, pp.8, 2014, https://doi.org/10.2967/jnumed.114.137166
- Bedeutung der PET für die Chirurgie des gastrointestinalen Stromatumors vol.85, pp.6, 2014, https://doi.org/10.1007/s00104-013-2670-1
- Spectrum of the prostate lesions with increased FDG uptake on 18F-FDG PET/CT vol.39, pp.4, 2011, https://doi.org/10.1007/s00261-014-0114-0
- A case of superficial esophageal carcinoma with papilloma resected by en bloc endoscopic submucosal dissection vol.11, pp.3, 2011, https://doi.org/10.1007/s10388-013-0403-7
- Bedeutung der PET für die Chirurgie des gastrointestinalen Stromatumors vol.37, pp.3, 2011, https://doi.org/10.1007/s00053-015-0525-6
- Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors vol.10, pp.6, 2011, https://doi.org/10.1371/journal.pone.0127800
- Correlation between the Uptake of 18 F-Fluorodeoxyglucose ( 18 F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis vol.10, pp.6, 2011, https://doi.org/10.1371/journal.pone.0129028
- Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to ¹⁸F-fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors vol.10, pp.10, 2015, https://doi.org/10.1371/journal.pone.0141413
- The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour vol.26, pp.12, 2011, https://doi.org/10.1007/s00330-016-4242-5
- Gastrointestinal stromal tumours (GISTs): an insight into clinical practice with review of literature vol.8, pp.1, 2011, https://doi.org/10.1136/flgastro-2015-100670
- Fractal analysis of contrast-enhanced CT images for preoperative prediction of malignant potential of gastrointestinal stromal tumor vol.43, pp.10, 2011, https://doi.org/10.1007/s00261-018-1526-z
- Multiparametric MRI and 18F-FDG PET features for differentiating gastrointestinal stromal tumors from benign gastric subepithelial lesions vol.30, pp.3, 2011, https://doi.org/10.1007/s00330-019-06534-9
- Metabolic behavior and prognostic role of pretreatment 18F‐FDG PET/CT in gist vol.16, pp.5, 2011, https://doi.org/10.1111/ajco.13366
- Case report of portal hepatic schwannoma: presentation of multimodality images vol.21, pp.1, 2011, https://doi.org/10.1186/s12876-021-01767-9